PGT-A, or preimplantation genetic testing for aneuploidies, is the process of screening IVF embryos for chromosome abnormalities prior to transfer, with the goal of increasing the likelihood of achieving a successful pregnancy. PGT-A was formerly known as PGS, preimplantation genetic screening. This process uses next-generation sequencing, the most cutting edge technology available today, to screen embryos for aneuploidy, providing the most accurate results.
The growth of an embryo into a baby is guided by its chromosomes. When the embryo is missing or has extra chromosomes, the condition is known as aneuploidy. An aneuploid embryo is an embryo that is missing or has extra chromosomes.
PGT-A is aimed at helping patients make informed decisions and improving their odds of IVF success.
Successful pregnancies begin with viable embryos
Aneuploid embryos are not usually viable. These embryos often fail to implant, and those that do, generally result in miscarriage. In cases where aneuploid embryos do develop to term, the most common condition is Down’s Syndrome which is a disorder associated with having three copies of chromosome 21.
Fortunately, PGT-A can accurately identify those embryos so only viable embryos are selected for implantation. PGT-A improves IVF success rates and also reduces high-risk multiple births by enabling the transfer of a single embryo.
PGT-A can eliminate the effect of maternal age on implantation. And, can reduce the negative effect of maternal age on miscarriage.
Aneuploidy exists across women of all age groups and increases with the woman’s age. Women over age 35 have almost double the risk of aneuploidy in comparison to younger women. When PGT-A is used to select embryos with the normal number of chromosomes, the negative effect of maternal age on implantation is eliminated, and, much lower miscarriage rates can be achieved.